WuXi AppTec
WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device outsourcing company.
WuXi AppTec, founded in December, 2000 and headquartered in Wuxi, is Ge Li. The founder is Ge Li. Listed on the HKEX on December 13, 2018, the company's major shareholders are HKSCC Nominees Ltd, G&C VI Ltd and Summer Bloom Investments (I) PTE. Ltd. Rivals that have direct and indirect competition with WuXi AppTec include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Sinopharm new coronavirus vaccine approved
Another protein component special medical food was approved, and the total number of approved products increased to 57
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
Research
Consumer Staples, Technology, HealthcareWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Consumer Discretionary, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
Research
Consumer Discretionary, Industrials, FinancialsLow-Carbon Industry Expansion - Key Studies From Chinese Companies
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Fosun medicine: the new crown vaccine has been included in the domestic phase II clinical, and no serious adverse report has been received
Cell and gene therapy cro / cdmo xuanming cells completed a round of financing, led by Huagai capital and juming venture capital
Improving service quality and enabling industrial innovation!
Pfizer submitted to FDA for authorization of emergency use of new crown vaccine
The new crown vaccine developed by academician Chen Wei and kangxinuo biology can be stable for a long time from 2 to 8 degrees
JW Therapeutics Studys on Adoptive T-cell Therapy with Lyell Immunopharma
TigerMed: New to be the Third Dual-listed CRO on HKEX and A-share
JW Therapeutics Buys Hong Kong Anti-cancer Drug Maker Syracuse Biopharma
JW Therapeutics’s CAR-T Therapy Goes Public, Second Candidate after FosunKite Biotech